SRAGE in diabetic and non-diabetic critically ill patients

Effects of intensive insulin therapy

Yaseen M. Arabi, Mohammed Dehbi, Asgar H. Rishu, Engin Baturcam, Salim H. Kahoul, Riette J. Brits, Brintha Naidu, Abderrezak Bouchama

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Introduction: Hyperglycemia represents an independent prognostic factor in critically ill non-diabetic patients but not in those with diabetes. In this context, there is an ongoing debate on the benefit of an intensive insulin therapy, particularly in diabetic patients. We tested the hypothesis that expression of the receptor for advanced glycation end-products (RAGE), an important signal transduction receptor that elicits long-lasting nuclear factor kappa B (NF-κB) activation, may underlie this difference. RAGE expression is regulated by multiple ligands, including high mobility group box-1 (HMGB-1), and is reflected by its released soluble form (sRAGE).Methods: A predesigned analysis was conducted of prospectively collected samples from 76 hyperglycemic critically ill patients (33 type-2 diabetes, 43 non-diabetes) aged ≥18 years with blood glucose of > 6.1 mmol/L enrolled in a randomized controlled trial comparing intensive insulin therapy with conventional insulin therapy. sRAGE and its ligand HMGB-1 together with IL-6, and soluble thrombomodulin (as markers of inflammation and endothelial cell injury, respectively) were evaluated in ICU, at Days 1, 3, 5 and 7. Plasma samples from 18 healthy subjects were used as controls.Results: Both diabetic and non-diabetic hyperglycemic patients showed increased plasma sRAGE, HMGB-1 and soluble thrombomodulin levels at the time of admission to ICU. Plasma IL-6 concentration was only increased in non-diabetic patients. Plasma levels of sRAGE were higher in diabetic compared with non-diabetic patients. Intensive insulin therapy resulted in a significant decrease of sRAGE and thrombomodulin at Day 7, in diabetic but not in non-diabetic patients. Circulating sRAGE levels correlated positively with IL-6 and soluble thrombomodulin levels and inversely with HMGB-1. Multivariate regression analysis demonstrated that sRAGE remains independently correlated with HMGB-1 only in diabetic patients. Neither sRAGE nor any inflammatory markers are associated with mortality.Conclusions: These findings support the hypothesis that sRAGE release, time-course and response to intensive insulin therapy differ between hyperglycemic diabetic and non-diabetic critically ill patients. Whether this difference underlies the dissimilarity in clinical outcome of hyperglycemia in these two conditions warrants further studies.

Original languageEnglish
Article numberR203
JournalCritical Care
Volume15
Issue number4
DOIs
Publication statusPublished - 26 Sep 2011
Externally publishedYes

Fingerprint

Critical Illness
Insulin
Thrombomodulin
Interleukin-6
Therapeutics
Hyperglycemia
Ligands
NF-kappa B
Type 2 Diabetes Mellitus
Blood Glucose
Signal Transduction
Healthy Volunteers
Multivariate Analysis
Randomized Controlled Trials
Endothelial Cells
Regression Analysis
Inflammation
Mortality
Wounds and Injuries

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Medicine(all)

Cite this

Arabi, Y. M., Dehbi, M., Rishu, A. H., Baturcam, E., Kahoul, S. H., Brits, R. J., ... Bouchama, A. (2011). SRAGE in diabetic and non-diabetic critically ill patients: Effects of intensive insulin therapy. Critical Care, 15(4), [R203]. https://doi.org/10.1186/cc10420

SRAGE in diabetic and non-diabetic critically ill patients : Effects of intensive insulin therapy. / Arabi, Yaseen M.; Dehbi, Mohammed; Rishu, Asgar H.; Baturcam, Engin; Kahoul, Salim H.; Brits, Riette J.; Naidu, Brintha; Bouchama, Abderrezak.

In: Critical Care, Vol. 15, No. 4, R203, 26.09.2011.

Research output: Contribution to journalArticle

Arabi, YM, Dehbi, M, Rishu, AH, Baturcam, E, Kahoul, SH, Brits, RJ, Naidu, B & Bouchama, A 2011, 'SRAGE in diabetic and non-diabetic critically ill patients: Effects of intensive insulin therapy', Critical Care, vol. 15, no. 4, R203. https://doi.org/10.1186/cc10420
Arabi, Yaseen M. ; Dehbi, Mohammed ; Rishu, Asgar H. ; Baturcam, Engin ; Kahoul, Salim H. ; Brits, Riette J. ; Naidu, Brintha ; Bouchama, Abderrezak. / SRAGE in diabetic and non-diabetic critically ill patients : Effects of intensive insulin therapy. In: Critical Care. 2011 ; Vol. 15, No. 4.
@article{52b7f1e706004c878a0681587b6da43a,
title = "SRAGE in diabetic and non-diabetic critically ill patients: Effects of intensive insulin therapy",
abstract = "Introduction: Hyperglycemia represents an independent prognostic factor in critically ill non-diabetic patients but not in those with diabetes. In this context, there is an ongoing debate on the benefit of an intensive insulin therapy, particularly in diabetic patients. We tested the hypothesis that expression of the receptor for advanced glycation end-products (RAGE), an important signal transduction receptor that elicits long-lasting nuclear factor kappa B (NF-κB) activation, may underlie this difference. RAGE expression is regulated by multiple ligands, including high mobility group box-1 (HMGB-1), and is reflected by its released soluble form (sRAGE).Methods: A predesigned analysis was conducted of prospectively collected samples from 76 hyperglycemic critically ill patients (33 type-2 diabetes, 43 non-diabetes) aged ≥18 years with blood glucose of > 6.1 mmol/L enrolled in a randomized controlled trial comparing intensive insulin therapy with conventional insulin therapy. sRAGE and its ligand HMGB-1 together with IL-6, and soluble thrombomodulin (as markers of inflammation and endothelial cell injury, respectively) were evaluated in ICU, at Days 1, 3, 5 and 7. Plasma samples from 18 healthy subjects were used as controls.Results: Both diabetic and non-diabetic hyperglycemic patients showed increased plasma sRAGE, HMGB-1 and soluble thrombomodulin levels at the time of admission to ICU. Plasma IL-6 concentration was only increased in non-diabetic patients. Plasma levels of sRAGE were higher in diabetic compared with non-diabetic patients. Intensive insulin therapy resulted in a significant decrease of sRAGE and thrombomodulin at Day 7, in diabetic but not in non-diabetic patients. Circulating sRAGE levels correlated positively with IL-6 and soluble thrombomodulin levels and inversely with HMGB-1. Multivariate regression analysis demonstrated that sRAGE remains independently correlated with HMGB-1 only in diabetic patients. Neither sRAGE nor any inflammatory markers are associated with mortality.Conclusions: These findings support the hypothesis that sRAGE release, time-course and response to intensive insulin therapy differ between hyperglycemic diabetic and non-diabetic critically ill patients. Whether this difference underlies the dissimilarity in clinical outcome of hyperglycemia in these two conditions warrants further studies.",
author = "Arabi, {Yaseen M.} and Mohammed Dehbi and Rishu, {Asgar H.} and Engin Baturcam and Kahoul, {Salim H.} and Brits, {Riette J.} and Brintha Naidu and Abderrezak Bouchama",
year = "2011",
month = "9",
day = "26",
doi = "10.1186/cc10420",
language = "English",
volume = "15",
journal = "Critical Care",
issn = "1466-609X",
publisher = "Springer Science + Business Media",
number = "4",

}

TY - JOUR

T1 - SRAGE in diabetic and non-diabetic critically ill patients

T2 - Effects of intensive insulin therapy

AU - Arabi, Yaseen M.

AU - Dehbi, Mohammed

AU - Rishu, Asgar H.

AU - Baturcam, Engin

AU - Kahoul, Salim H.

AU - Brits, Riette J.

AU - Naidu, Brintha

AU - Bouchama, Abderrezak

PY - 2011/9/26

Y1 - 2011/9/26

N2 - Introduction: Hyperglycemia represents an independent prognostic factor in critically ill non-diabetic patients but not in those with diabetes. In this context, there is an ongoing debate on the benefit of an intensive insulin therapy, particularly in diabetic patients. We tested the hypothesis that expression of the receptor for advanced glycation end-products (RAGE), an important signal transduction receptor that elicits long-lasting nuclear factor kappa B (NF-κB) activation, may underlie this difference. RAGE expression is regulated by multiple ligands, including high mobility group box-1 (HMGB-1), and is reflected by its released soluble form (sRAGE).Methods: A predesigned analysis was conducted of prospectively collected samples from 76 hyperglycemic critically ill patients (33 type-2 diabetes, 43 non-diabetes) aged ≥18 years with blood glucose of > 6.1 mmol/L enrolled in a randomized controlled trial comparing intensive insulin therapy with conventional insulin therapy. sRAGE and its ligand HMGB-1 together with IL-6, and soluble thrombomodulin (as markers of inflammation and endothelial cell injury, respectively) were evaluated in ICU, at Days 1, 3, 5 and 7. Plasma samples from 18 healthy subjects were used as controls.Results: Both diabetic and non-diabetic hyperglycemic patients showed increased plasma sRAGE, HMGB-1 and soluble thrombomodulin levels at the time of admission to ICU. Plasma IL-6 concentration was only increased in non-diabetic patients. Plasma levels of sRAGE were higher in diabetic compared with non-diabetic patients. Intensive insulin therapy resulted in a significant decrease of sRAGE and thrombomodulin at Day 7, in diabetic but not in non-diabetic patients. Circulating sRAGE levels correlated positively with IL-6 and soluble thrombomodulin levels and inversely with HMGB-1. Multivariate regression analysis demonstrated that sRAGE remains independently correlated with HMGB-1 only in diabetic patients. Neither sRAGE nor any inflammatory markers are associated with mortality.Conclusions: These findings support the hypothesis that sRAGE release, time-course and response to intensive insulin therapy differ between hyperglycemic diabetic and non-diabetic critically ill patients. Whether this difference underlies the dissimilarity in clinical outcome of hyperglycemia in these two conditions warrants further studies.

AB - Introduction: Hyperglycemia represents an independent prognostic factor in critically ill non-diabetic patients but not in those with diabetes. In this context, there is an ongoing debate on the benefit of an intensive insulin therapy, particularly in diabetic patients. We tested the hypothesis that expression of the receptor for advanced glycation end-products (RAGE), an important signal transduction receptor that elicits long-lasting nuclear factor kappa B (NF-κB) activation, may underlie this difference. RAGE expression is regulated by multiple ligands, including high mobility group box-1 (HMGB-1), and is reflected by its released soluble form (sRAGE).Methods: A predesigned analysis was conducted of prospectively collected samples from 76 hyperglycemic critically ill patients (33 type-2 diabetes, 43 non-diabetes) aged ≥18 years with blood glucose of > 6.1 mmol/L enrolled in a randomized controlled trial comparing intensive insulin therapy with conventional insulin therapy. sRAGE and its ligand HMGB-1 together with IL-6, and soluble thrombomodulin (as markers of inflammation and endothelial cell injury, respectively) were evaluated in ICU, at Days 1, 3, 5 and 7. Plasma samples from 18 healthy subjects were used as controls.Results: Both diabetic and non-diabetic hyperglycemic patients showed increased plasma sRAGE, HMGB-1 and soluble thrombomodulin levels at the time of admission to ICU. Plasma IL-6 concentration was only increased in non-diabetic patients. Plasma levels of sRAGE were higher in diabetic compared with non-diabetic patients. Intensive insulin therapy resulted in a significant decrease of sRAGE and thrombomodulin at Day 7, in diabetic but not in non-diabetic patients. Circulating sRAGE levels correlated positively with IL-6 and soluble thrombomodulin levels and inversely with HMGB-1. Multivariate regression analysis demonstrated that sRAGE remains independently correlated with HMGB-1 only in diabetic patients. Neither sRAGE nor any inflammatory markers are associated with mortality.Conclusions: These findings support the hypothesis that sRAGE release, time-course and response to intensive insulin therapy differ between hyperglycemic diabetic and non-diabetic critically ill patients. Whether this difference underlies the dissimilarity in clinical outcome of hyperglycemia in these two conditions warrants further studies.

UR - http://www.scopus.com/inward/record.url?scp=80053305598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053305598&partnerID=8YFLogxK

U2 - 10.1186/cc10420

DO - 10.1186/cc10420

M3 - Article

VL - 15

JO - Critical Care

JF - Critical Care

SN - 1466-609X

IS - 4

M1 - R203

ER -